{"id":1002675,"date":"2026-09-10T14:15:49","date_gmt":"2026-09-10T18:15:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/"},"modified":"2026-09-10T14:15:49","modified_gmt":"2026-09-10T18:15:49","slug":"big-pharma-setbacks-create-a-new-wave-of-rebound-plays","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/","title":{"rendered":"Big Pharma Setbacks Create a New Wave of Rebound Plays"},"content":{"rendered":"
\n

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) — The biotech tape delivered a brutal reminder of one of the sector\u2019s oldest rules:\u00a0even a fundamentally strong company can get caught in the crossfire when a major drugmaker suffers a pipeline setback.<\/strong> Yesterday, a setback at Novartis (NYSE: NVS) sent ripples across the biotech space, pressuring companies whose own clinical and corporate announcements remained decidedly positive.<\/p>\n

The resulting selloff highlighted just how quickly investors can shift from company-specific fundamentals to broader sector risk. For smaller biotech names, that indiscriminate pressure can be painful, but it can also create potentially compelling rebound setups when positive catalysts remain intact and the underlying thesis has not materially changed.<\/p>\n

When Novartis\u2019 Phase 3 Lp(a)HORIZON study for pelacarsen fell short on cardiovascular events, despite successfully lowering Lp(a), and del-desiran\u2019s Phase 3 HARBOR primary endpoint, Novartis shares suffered one of their worst-ever daily declines and also pressured companies developing unrelated therapies.<\/p>\n

That is where the setup gets interesting for smaller biotech names. The market demonstrated that it is willing to sell first and differentiate later. For traders hunting the next leg rather than chasing yesterday\u2019s winners, that kind of indiscriminate pressure can create exactly the type of dislocation worth watching.<\/p>\n

\n Novartis: 2 Missed Expectations, 1 Massive Sector Shock<\/strong>\n <\/p>\n

Novartis (NYSE:NVS) became the epicenter of the current biotech risk-off wave. Pelacarsen failed to demonstrate a reduction in cardiovascular events even though it achieved substantial Lp(a) lowering, challenging assumptions surrounding one of the industry’s most closely watched emerging cardiovascular targets. Novartis said the findings provide \u201cimportant new evidence\u201d about the relationship between Lp(a) lowering and cardiovascular outcomes.<\/p>\n

Then the second shoe dropped. Del-desiran failed to achieve the primary endpoint in the Phase 3 HARBOR study in myotonic dystrophy type 1. Novartis said the drug showed evidence of activity in secondary endpoints and exploratory analyses, but the primary endpoint, video hand opening time, was not statistically significant versus placebo.<\/p>\n

The market reaction was severe. Reuters reported that the del-desiran news sent Novartis shares down roughly 10.9% in one session and erased about $32 billion in market value. The company has maintained its 5%-6% five-year sales CAGR guidance, but investors are now looking much harder at the remaining pipeline.<\/p>\n

For the broader biotech market, however, the important takeaway may be less about Novartis itself and more about correlation risk<\/strong>. When a major drugmaker disappoints, investors frequently punish companies sharing a mechanism, indication or perceived development theme, even when those smaller companies have independent data. That creates both danger and opportunity.<\/p>\n

\n That Juxtaposition is the Story<\/strong>\n <\/p>\n

The following are some of the companies that produced legitimate wins and were held down, as the unrelated news traveled directly down the market-cap spectrum. Traders should distinguish between a company whose own thesis has broken and a company that simply got caught in a sector-wide liquidation. Those are two very different setups and the rebound becomes the play.<\/p>\n

\n NeOnc Technologies Holdings: $15M Funding Sets New Number to Watch<\/strong>\n <\/p>\n

NeOnc (NASDAQ:NTHI) enters the rebound conversation with something many small biotechs desperately need: clinical data plus fresh capital.<\/strong> The company recently reported Phase 2a results for intranasal NEO100 in recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. Six-month progression-free survival was 48.9%, versus a prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was 26.09 months.<\/p>\n

Then came the financing. NeOnc announced a roughly $15 million registered direct offering priced at $4.20 per share<\/strong>, or pre-funded warrants in certain cases, with accompanying warrants also exercisable at $4.20. The transaction was described as priced at-the-market under Nasdaq rules.<\/p>\n

The $4.20 figure is therefore a key reference point. It is reasonable for traders to view an at-the-market institutional financing price as a potentially meaningful valuation reference that the company is intrinsically worth more than $4.20.<\/p>\n

The clinical catalyst remains the bigger story. NeOnc plans to request a Type B FDA meeting to discuss a potential registrational pathway for NEO100. If the broader biotech tape stabilizes, NTHI has the ingredients for a rebound narrative: fresh financing, a defined clinical catalyst and a previously reported efficacy signal.<\/p>\n

\n Tenon Medical: Dilution Overhang Eliminated <\/strong>\n <\/p>\n

Tenon (NASDAQ:TNON) offers a different type of setup. The company announced that it repaid its approximately $5.16 million<\/strong> of outstanding original-issue-discount senior convertible notes ahead of their September 11 maturity date. The notes were issued in March and had the potential to convert into common shares at a discount to market prices.<\/p>\n

That matters because small-cap traders often focus on the clinical or commercial catalyst while ignoring the capital structure. Convertible debt can become a persistent source of selling pressure when holders have an economic incentive to convert shares below prevailing market prices.<\/p>\n

Tenon’s repayment removes that particular overhang. CEO Steven M. Foster said: \u201cBy proactively addressing this obligation, we are reducing potential dilution for our shareholders, strengthening our financial position and maintaining greater flexibility to invest in the continued commercialization of our products and expansion of our business.\u201d<\/strong><\/p>\n

That doesn’t magically eliminate execution risk, but it changes the trading equation.<\/p>\n

\n Opus Genetics: Positive Data Meets a Brutal Biotech Tape<\/strong>\n <\/p>\n

Opus Genetics (NASDAQ:IRD) may be one of the clearest examples of the market’s current disconnect between company-specific news and sector-level price action<\/strong>. The company reported positive three- and six-month results from Cohort 1 of its Phase 1\/2 BIRD-1 study evaluating OPGx-BEST1 in BEST1-related inherited retinal diseases. All five participants demonstrated clinically meaningful improvements in at least one visual-function measure, while structural improvements were observed in four participants.<\/p>\n

The company reported best-corrected visual-acuity improvement in three of five participants and improved retinal sensitivity by microperimetry in three of four evaluable participants. No serious adverse events or dose-limiting toxicities were reported in the cohort, according to the company.<\/p>\n

More importantly for the forward-looking story, Opus has been working toward a potential pivotal program. The company previously said its FDA interactions could support a pivotal endpoint involving microperimetry and a patient-reported outcome, with potential Phase 3 dosing targeted for 2027.<\/p>\n

That creates the kind of setup where consolidation could matter more than another headline spike. After a big move, digestion of gains can establish a new base; if the stock holds that base while the pipeline continues advancing, another leg becomes technically possible.<\/p>\n

\n About 24\/7 Market News<\/strong>\n <\/p>\n

In today’s fast-moving markets, visibility is everything and 24\/7 Market News (24\/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company\u2019s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24\/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com<\/u><\/a> to discuss how 24\/7 can help accelerate your company\u2019s visibility and valuation trajectory.<\/p>\n

This is a paid editorial communication intended for informational purposes only. 24\/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here<\/u><\/a>. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.<\/p>\n

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.<\/p>\n

\n CONTACT:<\/strong>
\n
24\/7 Market News
Editor@247mnn.com<\/u><\/a><\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) — The biotech tape delivered a brutal reminder of one of the sector\u2019s oldest rules:\u00a0even a fundamentally strong company can get caught in the crossfire when a major drugmaker suffers a pipeline setback. Yesterday, a setback at Novartis (NYSE: NVS) sent ripples across the biotech space, pressuring companies whose own clinical and corporate announcements remained decidedly positive. The resulting selloff highlighted just how quickly investors can shift from company-specific fundamentals to broader sector risk. For smaller biotech names, that indiscriminate pressure can be painful, but it can also create potentially compelling rebound setups when positive catalysts remain intact and the underlying thesis has not materially changed. When Novartis\u2019 Phase 3 Lp(a)HORIZON study for pelacarsen … <\/p>\n

Continue reading “Big Pharma Setbacks Create a New Wave of Rebound Plays”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1002675","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBig Pharma Setbacks Create a New Wave of Rebound Plays - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Big Pharma Setbacks Create a New Wave of Rebound Plays - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) — The biotech tape delivered a brutal reminder of one of the sector\u2019s oldest rules:\u00a0even a fundamentally strong company can get caught in the crossfire when a major drugmaker suffers a pipeline setback. Yesterday, a setback at Novartis (NYSE: NVS) sent ripples across the biotech space, pressuring companies whose own clinical and corporate announcements remained decidedly positive. The resulting selloff highlighted just how quickly investors can shift from company-specific fundamentals to broader sector risk. For smaller biotech names, that indiscriminate pressure can be painful, but it can also create potentially compelling rebound setups when positive catalysts remain intact and the underlying thesis has not materially changed. When Novartis\u2019 Phase 3 Lp(a)HORIZON study for pelacarsen … Continue reading "Big Pharma Setbacks Create a New Wave of Rebound Plays"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-10T18:15:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDgyOCM3ODI3ODYyIzIzMDQzNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Big Pharma Setbacks Create a New Wave of Rebound Plays\",\"datePublished\":\"2026-09-10T18:15:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\\\/\"},\"wordCount\":1426,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNDgyOCM3ODI3ODYyIzIzMDQzNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\\\/\",\"name\":\"Big Pharma Setbacks Create a New Wave of Rebound Plays - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNDgyOCM3ODI3ODYyIzIzMDQzNjM=\",\"datePublished\":\"2026-09-10T18:15:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNDgyOCM3ODI3ODYyIzIzMDQzNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNDgyOCM3ODI3ODYyIzIzMDQzNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Big Pharma Setbacks Create a New Wave of Rebound Plays\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Big Pharma Setbacks Create a New Wave of Rebound Plays - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/","og_locale":"en_US","og_type":"article","og_title":"Big Pharma Setbacks Create a New Wave of Rebound Plays - Market Newsdesk","og_description":"DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) — The biotech tape delivered a brutal reminder of one of the sector\u2019s oldest rules:\u00a0even a fundamentally strong company can get caught in the crossfire when a major drugmaker suffers a pipeline setback. Yesterday, a setback at Novartis (NYSE: NVS) sent ripples across the biotech space, pressuring companies whose own clinical and corporate announcements remained decidedly positive. The resulting selloff highlighted just how quickly investors can shift from company-specific fundamentals to broader sector risk. For smaller biotech names, that indiscriminate pressure can be painful, but it can also create potentially compelling rebound setups when positive catalysts remain intact and the underlying thesis has not materially changed. When Novartis\u2019 Phase 3 Lp(a)HORIZON study for pelacarsen … Continue reading \"Big Pharma Setbacks Create a New Wave of Rebound Plays\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-10T18:15:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDgyOCM3ODI3ODYyIzIzMDQzNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Big Pharma Setbacks Create a New Wave of Rebound Plays","datePublished":"2026-09-10T18:15:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/"},"wordCount":1426,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDgyOCM3ODI3ODYyIzIzMDQzNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/","name":"Big Pharma Setbacks Create a New Wave of Rebound Plays - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDgyOCM3ODI3ODYyIzIzMDQzNjM=","datePublished":"2026-09-10T18:15:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDgyOCM3ODI3ODYyIzIzMDQzNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDgyOCM3ODI3ODYyIzIzMDQzNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/big-pharma-setbacks-create-a-new-wave-of-rebound-plays\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Big Pharma Setbacks Create a New Wave of Rebound Plays"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1002675"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002675\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1002675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1002675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1002675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}